First Patient Treated In Osiris Phase II Stem Cell Trial For Heart Attacks
Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced the treatment of the first patient in a Phase II clinical trial evaluating Prochymal for the treatment of heart attacks. The first patient, a 58-year old man, was treated at the Heart Hospital of Austin, Texas. Prochymal is a proprietary formulation of adult stem cells designed to provide therapeutic benefit by controlling inflammation, promoting tissue regeneration, and preventing scar formation.
[Read the full article here]Related News:
Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction (Centre Daily Times)
Heart Hospital Of Austin First Site In World To Test Efficacy Of New Adult Stem Cell Therapy To Treat Damaged Heart Tissue In Phase II Trial
Osiris Therapeutics Completes Enrollment Of Stem Cell Trial For The Treatment Of Heart Attacks